DermTech Pledges up to $1 Million to Raise Awareness and Support Accessibility of Skin Exams
May 03 2021 - 4:30PM
Business Wire
Leading Precision Dermatology Company Launches
#Stickit2Melanoma™ Campaign to Join the Pledge to Stop Melanoma
Deaths
In honor of Melanoma and Skin Cancer Awareness Month, DermTech,
Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology
enabled by the non-invasive DermTech Smart Sticker™ platform and
its melanoma test, the Pigmented Lesion Assay or PLA, is launching
the #Stickit2Melanoma campaign, urging the public to get proactive
about skin exams. One in five Americans develop skin cancer by the
age of 70, and every hour of every day one American dies from
melanoma. It is not only one of the most common cancers diagnosed
in the U.S., but also the deadliest of skin cancers. Yet, when
diagnosed at a localized stage, the 5-year relative survival rate
for melanoma is 99%. Early detection saves lives, and just one
annual screening can uncover issues beneath the skin’s surface at
the most treatable stage.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210503005684/en/
#Stickit2Melanoma
To kick off the campaign, DermTech is pledging up to $1 million
over the next four years to raise awareness about the importance of
skin exams and making them accessible to everyone. For every
#Stickit2Melanoma pledge to schedule a skin exam with a clinician,
DermTech will make a $5 donation to its nonprofit partner
organizations focused on skin health. DermTech believes it can help
stop deaths from melanoma and is steadfast in fulfilling this
goal.
“DermTech is fervently committed to reducing melanoma deaths
through early detection, and this pledge is just the start to a
bigger movement we are hoping to inspire,” said John Dobak, M.D.,
Chief Executive Officer of DermTech. “The technology and science to
reduce melanoma deaths through early and accurate detection is
here, so no one should ever have to die from this cancer. To make
this possible, we’re calling on everyone–dermatologists and
patients alike–to galvanize their communities to join our pledge
today.”
#Stickit2Melanoma aims to bring awareness to the dangers of
late-stage melanoma and the life-saving effects of scheduling skin
exams. DermTech’s donations will help support events, educational
content and programs to amplify a variety of voices who are joining
our fight to end melanoma deaths. DermTech is proud to serve as a
partner to the dermatology community and an ally to skin cancer
organizations across the country.
To join #Stickit2Melanoma, schedule a skin exam with your
doctor, take the pledge at www.DermTech.com/Pledge and encourage
your community to do the same. Let’s unite together to end melanoma
deaths.
About DermTech:
DermTech is the leading genomics company in dermatology and is
creating a new category of medicine, precision dermatology, enabled
by our non-invasive skin genomics platform. DermTech’s mission is
to transform dermatology with our non-invasive skin genomics
platform, to democratize access to high quality dermatology care,
and to improve the lives of millions. DermTech provides genomic
analysis of skin samples collected non-invasively using an adhesive
patch rather than a scalpel. DermTech markets and develops products
that facilitate the early detection of skin cancers, and is
developing products that assess inflammatory diseases and customize
drug treatments. For additional information on DermTech, please
visit DermTech’s investor relations site at: www.dermtech.com.
Forward-Looking Statements:
This press release includes “forward-looking statements” within
the meaning of the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1995. The expectations,
estimates, and projections of DermTech may differ from its actual
results and consequently, you should not rely on these
forward-looking statements as predictions of future events. Words
such as “expect,” “estimate,” “project,” “budget,” “forecast,”
“anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,”
“believes,” “predicts,” “potential,” “continue,” and similar
expressions are intended to identify such forward-looking
statements. These forward-looking statements include, without
limitation, expectations with respect to: the performance, patient
benefits, cost-effectiveness, commercialization and adoption of
DermTech’s products and the market opportunity therefor. These
forward-looking statements involve significant risks and
uncertainties that could cause the actual results to differ
materially from the expected results. Most of these factors are
outside of the control of DermTech and are difficult to predict.
Factors that may cause such differences include, but are not
limited to: (1) the outcome of any legal proceedings that may be
instituted against DermTech; (2) DermTech’s ability to obtain
additional funding to develop and market its products; (3) the
existence of favorable or unfavorable clinical guidelines for
DermTech’s tests; (4) the reimbursement of DermTech’s tests by
Medicare and private payors; (5) the ability of patients or
healthcare providers to obtain coverage of or sufficient
reimbursement for DermTech’s products; (6) DermTech’s ability to
grow, manage growth and retain its key employees; (7) changes in
applicable laws or regulations; (8) the market adoption and demand
for DermTech’s products and services together with the possibility
that DermTech may be adversely affected by other economic,
business, and/or competitive factors; and (9) other risks and
uncertainties included in (x) the “Risk Factors” section of the
most recent Annual Report on Form 10-K filed by DermTech with the
Securities and Exchange Commission (the “SEC”), and (y) other
documents filed or to be filed by DermTech with the SEC. DermTech
cautions that the foregoing list of factors is not exclusive. You
should not place undue reliance upon any forward-looking
statements, which speak only as of the date made. DermTech does not
undertake or accept any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
to reflect any change in its expectations or any change in events,
conditions, or circumstances on which any such statement is
based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210503005684/en/
DermTech Sarah Dion sdion@dermtech.com 858.450.4222
Crowe PR Sarah Gallagher sgallagher@crowepr.com 224.406.4709
DermTech (NASDAQ:DMTK)
Historical Stock Chart
From Mar 2024 to Apr 2024
DermTech (NASDAQ:DMTK)
Historical Stock Chart
From Apr 2023 to Apr 2024